Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements

This study has been completed.
Proliant Health & Biologicals
Information provided by (Responsible Party):
University of California, Davis Identifier:
First received: March 10, 2011
Last updated: March 22, 2017
Last verified: January 2017
Results First Received: September 15, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Condition: HIV
Intervention: Dietary Supplement: Immunolin®

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients with diagnosis of HIV enteropathy are eligible for enrollment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
ImmunoLin® 2.5 grams twice daily for eight weeks

Participant Flow:   Overall Study

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
ImmunoLin® 8-week treatment course

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
Count of Participants
<=18 years      0   0.0% 
Between 18 and 65 years      8 100.0% 
>=65 years      0   0.0% 
[Units: Years]
Mean (Standard Deviation)
 44.5  (4.5) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      0   0.0% 
Male      8 100.0% 
Region of Enrollment 
[Units: Participants]
United States   8 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Bowel Movements Per Day   [ Time Frame: 8 weeks (56 days) ]

2.  Secondary:   Frequency of Pro-inflammatory Bacterial Orders   [ Time Frame: 8 weeks ]

3.  Secondary:   Measures of Gut Permeability   [ Time Frame: 8 weeks ]

4.  Secondary:   Systemic Immune Activation   [ Time Frame: 8 weeks ]

5.  Secondary:   Duodenal Immune Reconstitution   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
pilot open label study with eight subjects.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: David Asmuth, MD
Organization: UCaliforniaDavis
phone: 9167348695

Publications of Results:

Responsible Party: University of California, Davis Identifier: NCT01313910     History of Changes
Other Study ID Numbers: 225193 (201118675)
Study First Received: March 10, 2011
Results First Received: September 15, 2013
Last Updated: March 22, 2017